Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of the National Cancer Institute

• Publication date

  1993-10-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1093/JNCI/85.20.1685PMID 8105099
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cross-resistance of drug-resistant murine P388 leukemias to toxol in vivo

  2004cited by this paper
• Successful re-treatment with taxol after major hypersensitivity reactions.

  1993cited by this paper
• Taxol: the first of the taxanes, an important new class of antitumor agents.

  1992cited by this paper
• Reversal of multidrug resistance by surfactants.

  1992cited by this paper
• Phase I trial of Taxotere: five-day schedule.

  1992cited by this paper
• Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas.

  1992cited by this paper
• Levels of expression of the mdr1 gene and glutathione S-transferase genes 2 and 3 and response to chemotherapy in multiple myeloma.

  1992cited by this paper
• A phase I trial of taxol given by a 6-hour intravenous infusion.

  1991cited by this paper
• Solutol HS 15, nontoxic polyoxyethylene esters of 12-hydroxystearic acid, reverses multidrug resistance.

  1991cited by this paper
• Expression of P-glycoprotein in breast cancer tissue and in vitro resistance to doxorubicin and vincristine.

  1991cited by this paper
• Overexpression of P-glycoprotein and glutathione S-transferase-pi in resistant non-small cell lung carcinomas of smokers.

  1991cited by this paper
• An electron and fluorescence microscopic study of LLC-PK1 cells, a kidney epithelial cell line: normal morphology and cyclosporin A- and cremophor-induced alterations.

  1991cited by this paper
• Interaction of cremophor EL with human plasma.

  1991cited by this paper
• Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer.

  1991cited by this paper
• P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil.

  1991cited by this paper
• Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer

  1991cited by this paper
• Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood.

  1990cited by this paper
• The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance.

  1990cited by this paper
• Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs.

  1990cited by this paper
• The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.

  1990cited by this paper
• Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining.

  1989cited by this paper
• Mechanism of multidrug resistance.

  1988cited by this paper
• Taxol: mechanisms of action and resistance.

  1986cited by this paper
• Taxol: Mechanisms of Action and Resistance a

  1986cited by this paper
• Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.

  1985cited by this paper
• Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

  1979cited by this paper
• Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia.

  1971cited by this paper

• Disposition and fate of polyoxyethylene glycerol ricinoleate as determined by LC-Q-TOF MS coupled with MSALL, SWATH and HR MS/MS techniques

  2021cites this paper
• Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models

  2020cites this paper
• Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality

  2020cites this paper
• Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo

  2018cites this paper
• Title Disposition kinetics of taxanes in peritoneal dissemination

  2017cites this paper
• Effects of frequently used pharmaceutical excipients on the organic cation transporters 1–3 and peptide transporters 1/2 stably expressed in MDCKII cells

  2017cites this paper
• Paclitaxel-Development , Properties , Toxicity / Safety Evaluation and the Scope of Improvement

  2016cites this paper
• Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis

  2016cites this paper
• The role of ABC transporters in ovarian cancer progression and chemoresistance.

  2015cites this paper
• Nanosuspension delivery of paclitaxel to xenograft mice can alter drug disposition and anti-tumor activity

  2014cites this paper
• Strategies to Address Low Drug Solubility in Discovery and Development

  2013cites this paper
• Optimization of Paclitaxel Containing pH-Sensitive Liposomes By 3 Factor, 3 Level Box-Behnken Design

  2013cites this paper
• Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo

  2012cites this paper
• Emerging Drug Treatments for Solid Tumours

  2012cites this paper
• Pharmacokinetics and Biodistribution of Paclitaxel–Gelatin Nanoparticles

  2012cites this paper
• Disposition Kinetics of Taxanes in Peritoneal Dissemination

  2012cites this paper
• Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery

  2011cites this paper
• Paclitaxel-loaded polyester nanoparticles prepared by spray-drying technology: in vitro bioactivity evaluation

  2011cites this paper
• Plant-Derived Natural Products as Anticancer Agents

  2011cites this paper
• characterization of paclitaxel nanosuspension Particle size and polydispersity index ( PI )

  2011cites this paper
• Preparation and characterization of chitosan–polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel

  2011cites this paper
• Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process

  2011cites this paper
• Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors.

  2010cites this paper
• Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.

  2010cites this paper
• Novel Mixed Polymeric Micelles for Enhancing Delivery of Anticancer Drug and Overcoming Multidrug Resistance in Tumor Cell Lines Simultaneously

  2010cites this paper
• Cytotoxicity of fractionated paclitaxel (Taxol®) administration in vitro

  2009cites this paper
• Novel self-assembling PEG-p-(CL-co-TMC) polymeric micelles as safe and effective delivery system for paclitaxel.

  2009cites this paper
• INFLUENCE OF LIPOSOME COMPOSITION ON PACLITAXEL ENTRAPMENT AND pH SENSITIVITY OF LIPOSOMES

  2009cites this paper
• Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

  2009cites this paper
• Plasma alcohol concentrations in patients following paclitaxel infusion

  2009cites this paper
• Paclitaxel chemotherapy for the treatment of gastric cancer

  2009cites this paper
• Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery.

  2008cites this paper
• Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment.

  2007cites this paper
• P-glycoprotein and membrane permeability as determinants of xenobiotic bioavailability and bioaccumulation

  2007cites this paper
• Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

  2007cites this paper
• The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

  2006cites this paper
• LC‐MS/MS for Determination of Paclitaxel in Rat Tissues: Application to a Biodistribution Study of Paclitaxel Nanoliposome Modified by PEO‐PPO‐PEO Triblock Copolymers

  2006cites this paper
• Liquid chromatography/tandem triple-quadrupole mass spectrometry for determination of paclitaxel in rat tissues.

  2006cites this paper
• Multidrug transporters as drug targets.

  2006cites this paper
• Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation.

  2005cites this paper
• Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity.

  2005cites this paper
• Preparation and characterization of taxane-containing liposomes.

  2005cites this paper
• Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

  2004cites this paper
• Complement Activation-Related Pseudoallergy

  2004cites this paper
• Current status of paclitaxel in the treatment of breast cancer

  2004cites this paper
• Metabolism of taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences

  2004cites this paper
• Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.

  2004cites this paper
• Pharmacological Effects of Formulation Vehicles

  2003cites this paper
• Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases

  2003cites this paper
• A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

  2003cites this paper
• Tubulin interacting agents: Novel taxanes and epothilones

  2003cites this paper
• Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs

  2002cites this paper
• Non‐Sedating Antihistamines for Premedication in Ambulatory Oncology Patients

  2002cites this paper
• Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.

  2002cites this paper
• Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

  2002cites this paper
• Pluronic block copolymers for overcoming drug resistance in cancer.

  2002cites this paper
• Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers.

  2002cites this paper
• Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol

  2002cites this paper
• Phase I and Pharmacokinetic Study of ABI-007 , a Cremophor-free , Protein-stabilized , Nanoparticle Formulation of Paclitaxel 1

  2002cites this paper
• Paclitaxel in cancer therapy

  2002cites this paper
• Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study

  2002cites this paper
• Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol).

  2002cites this paper
• A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

  2002cites this paper
• Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

  2001cites this paper
• Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients

  2001cites this paper
• Modulation of radiation-induced organs toxicity by cremophor-el in experimental animals.

  2001cites this paper
• Role of Formulation Vehicles in Taxane Pharmacology

  2001cites this paper
• Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers.

  2001cites this paper
• Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.

  2001cites this paper
• Clinical and pharmacokinetic data of a docetaxel-epirubicin combination in metastatic breast cancer

  2001cites this paper
• Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.

  2001cites this paper
• Pharmacokinetic profiles of doxorubicin in combination with taxanes.

  2001cites this paper
• Determination of Cremophor EL in plasma after sample preparation with solid phase extraction and plasma protein precipitation.

  2001cites this paper
• Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy

  2001cites this paper
• Pharmacologic aspects of new classes of anti-cancer agents: inhibitors of topoisomerase I or tubulin

  2001cites this paper
• Photodynamic therapy against achromic M6 melanocytes: phototoxicity of lipophilic axially substituted aluminum phthalocyanines and hexadecahalogenated zinc phthalocyanines

  2001cites this paper
• Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

  2000cites this paper
• Sequence E ffect o f E pirubicin a nd P aclitaxel T reatment o n Pharmacokinetics a nd T oxicity

  2000cites this paper
• Pharmacologic modulation of taxanes

  2000cites this paper
• Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients

  2000cites this paper
• Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.

  2000cites this paper
• Multidrug Resistance Phenotype and Paclitaxel (Taxol®) Sensitivity in Human Renal Carcinoma Cell Lines of Different Histologic Types

  2000cites this paper
• Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.

  2000cites this paper
• A Phase II Study of Paclitaxel/Cisplatin Combination in Patients with Metastatic Breast Cancer Refractory to Anthracycline-Based Chemotherapy

  2000cites this paper
• Inhibition of P-Glycoprotein by D-α-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS)

  1999cites this paper
• Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatment

  1999influential citation
• Development of nonionic surfactant/phospholipid o/w emulsion as a paclitaxel delivery system.

  1999cites this paper
• Interaction of paclitaxel (Taxol®) and irradiation

  1999cites this paper
• Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS).

  1999cites this paper
• Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions.

  1999cites this paper
• On pushing the outer edge of the outer edge of paclitaxel's dosing envelope.

  1999cites this paper
• Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids.

  1999cites this paper
• Pharmacologic study of Cremophor EL in cancer patients with impaired hepatic function receiving paclitaxel

  1999cites this paper
• Photodynamic activities of silicon phthalocyanines against achromic M6 melanoma cells and healthy human melanocytes and keratinocytes.

  1999cites this paper
• Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.

  1999cites this paper
• Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL

  1999cites this paper
• Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).

  1999cites this paper
• Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report.

  1998cites this paper
• Inhibition of the ATP‐sensitive potassium channel from mouse pancreatic β‐cells by surfactants

  1998influential citation
• Cell line and schedule-dependent cytotoxicity of paclitaxel (Taxol): role of the solvent Cremophor EL/ethanol.

  1998cites this paper